publication date: Oct. 20, 2016
Renal Cell Carcinoma Durable Responses Seen With Opdivo and Yervoy in Updated Analysis
Updated results of the phase I CheckMate-016 trial include findings for the Opdivo (sunitinib) and Yervoy (pazopanib) combinations showed the overall response rate (ORR; secondary endpoint) was 40.4% (n=47) in both arms.
The two drugs are sponsored by Bristol-Myers Squibb.
The trial, which now has two years of follow-up, compared 3 mg/kg plus Yervoy 1 mg/kg in one arm with Opdivo 1 mg/kg plus Yervoy 3 mg/kg in the other arm.
Of the 38 responders in both treatment arms, 39.5% (n=15) had an ongoing response, with a median duration of response of 20.4 months (95% CI: 8.54 – NE) in the Opdivo 3 mg/kg plus Yervoy 1 mg/kg arm and 19.7 months (95% CI: 8.08 – NE) in the Opdivo 1 mg/kg plus Yervoy 3 mg/kg arm.
The overall survival rate at 12 months was 81% and 85% for Opdivo 3 mg/kg plus Yervoy 1 mg/kg arm and Opdivo 1 mg/kg plus Yervoy 3 mg/kg arm, respectively, and at 24 months was 67% and 70%, respectively. There were fewer Grade 3/4 treatment-related adverse events reported in the Opdivo 3 mg/kg plus Yervoy 1 mg/kg arm (38.3%) than with Opdivo 1 mg/kg plus Yervoy 3 mg/kg arm (61.7%).
These results were presented at the 2016 European Society for Medical … Continue reading CCL Oct 2016 – Durable Responses Seen With Opdivo and Yervoy in Updated Analysis
To access this members-only content, please log in.
If you're not a subscriber why not join today?
If you believe you should be able to view this area but cannot log in, then please contact us
and we will try to rectify this issue as soon as possible.
To gain access to the members only content click here
You will be given immediate access to premium content on the site.Click here to join.